BMP-7 blocks the cyclosporine-a-induced epithelial-to-mesenchymal transition in renal tubular epithelial cells

Nephron - Experimental Nephrology

Volumn 114, Issue 1, 2010, Pages

  Xu, Yanfang ^a   Wan, Jianxin ^a   Jiang, Dewen ^a   Wu, Xiaonan ^b  

^a First Affiliated Hospital   (China)

^b FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Bone morphogenetic protein 7; Connective tissue growth factor; Cyclosporine A; Transforming growth factor ; Transition

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOSPORIN A; RECOMBINANT OSTEOGENIC PROTEIN 1; SMALL INTERFERING RNA; UVOMORULIN;

ARTICLE; CELL CULTURE; CELL STRUCTURE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; KIDNEY INJURY; KIDNEY TUBULE EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; UPREGULATION;

BONE MORPHOGENETIC PROTEIN 7; CELL DIFFERENTIATION; CELL LINE; CYCLOSPORINE; DRUG INTERACTIONS; EPITHELIAL CELLS; HUMANS; KIDNEY TUBULES; MESENCHYMAL STEM CELLS;

EID: 70349830105     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000245063     Document Type: Article

References (22)

1. Esposito C, Fornoni A, Cornacchia F, Bellotti N, Fasoli G, Foschi A, Mazzucchelli I, Mazzullo T, Semeraro L, Dal Canton A: Cyclosporine induces different responses in human epithelial, endothelial and fibroblast cell cultures. Kidney Int 2000; 58:123-130.
2. McMorrow T, Gaffney MM, Slattery C, Campbell E, Ryan MP: Cyclosporine A induced epithelial-mesenchymal transition in human renal proximal tubular epithelial cells. Nephrol Dial Transplant 2005; 20: 2215-2225.
3. Yokoi H, Mukoyama M, Nagae T, Mori K, Suganami T, Sawai K, Yoshioka T, Koshikawa M, Nishida T, Takigawa M, Sugawara A, Nakao K: Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-1440.
4. Liu Y: Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic inter vention. J Am Soc Nephrol 2004; 15: 1-12.
5. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P: Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 2006; 17:2484-2494.
6. Niksic L, Martin PY: Bone morphogenetic protein-7: a future treatment for chronic renal failure? Rev Med Suisse 2005; 1:568-570, 572-573.
7. 1-induced epithelial-tomesenchymal transition and reverses chronic renal injury. Nat Med 2003; 9:964-968.
8. Wang SN, Hirschberg R: BMP-7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284: 1006-1013.
9. Zeisberg M: Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006; 21: 568-573.
10. Yang J, Liu Y: Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465-1475.
11. Oldfield MD, Bach LA, Forbes JM, et al: Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products. J Clin Invest 2001; 108:1853-1863.
12. Lan HY: Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003; 12:25-29.
13. Van Nieuwenhoven FA, Jensen LJ, Flyvbjerg A, Goldschmeding R: Imbalance of growth factor signalling in diabetic kidney disease: Is connective tissue growth factor (CTGF, CCN2) the perfect intervention point? Nephrol Dial Transplant 2005; 20:6-10.
14. Ziyadeh FN: Mediators of diabetic renal disease: THE case for TGF-β as the major mediator. J Am Soc Nephrol 2004; 15(suppl 1): S55-S57.
15. Twigg SM, Cooper ME: The time has come to target connective tissue growth factor in diabetic complications. Diabetologia 2004; 47: 965-968.
16. Klahr S: The bone morphogenetic proteins. Their role in renal fibrosis and renal function. J Nephrol 2003; 16: 179-185.
17. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, Hruska KA: Bone morphogenic protein-7, a novel therapy for diabetic nephropathy. Kidney Int 2003; 63:2037-2049.
18. Reed CA, Peralta ER, Wenrich LM, Wong CA, Bennett CF, Freier S, Lollo B: Transfection protocol for antisense oligonucleotides affects uniformity of transfection in cell culture and efficiency of MRNA target reduction. Oligonucleotides 2005; 15: 12-22.
19. Chen Y, Blom IE, Sa S, Goldschmeding R, Abraham DJ, Leask A: CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int 2002; 62: 1149-1159.
20. Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ: Pentoxifylline attenuates tubulointerstitial fibrosis by blocking SMAD3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 2005; 16:2702-2713.
21. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA, et al: CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008; 19:2098-2107.
22. Mathew S, Davies M, Lund R, Saab G, Hruska KA: Function and effect of bone morphogenetic protein-7 in kidney bone and the bone-vascular links in chronic kidney disease. Eur J Clin Invest 2006; 36(suppl 2):43-50.